This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (28)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Diabetes Control and Complications Trial Research Group; Ronald Klein, MD; Scott Moss, MA; A

Arch Intern Med. 1995;155(7):745-754.

Abstract
Background
We compared the Diabetes Control and Complications Trial (DCCT) cohort with patients who had insulin-dependent diabetes mellitus (IDDM) in the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) to determine whether the DCCT cohort was similar to the patients with IDDM in the general population and whether the DCCT results are generalizable to a nonresearch population.

Methods
Demographic and clinical characteristics were compared between the DCCT study cohort and the WESDR cohort of patients with IDDM with age at onset of diabetes at younger than 30 years and followed up from 1980 to 1986. The DCCT eligibility criteria were applied to the WESDR cohort, and patients were identified who fulfilled the major criteria of the DCCT primary prevention and secondary intervention cohorts. Conventionally treated subjects in the DCCT primary prevention and secondary intervention cohorts were compared with their respective WESDR groups with regard to clinical characteristics, progression of retinopathy, and development of gross proteinuria.

Results
Comparison of the DCCT primary prevention and secondary intervention cohorts at baseline with the respective WESDR groups revealed an older age and an older age at diagnosis, a lower hemoglobin A_1c (HbA_1c) level, and more frequent injections and monitoring in the DCCT cohorts, but there were few other substantive differences. The progression of retinopathy and the association with baseline HbA_1c level were similar for the conventionally treated DCCT and WESDR cohorts, except for a lower rate of progression in the DCCT secondary intervention cohort compared with that of the WESDR cohort, perhaps because of the lower HbA_1c level.

Conclusions
At baseline, patients in the DCCT cohort were generally similar to patients with IDDM in the population-based WESDR cohort, except for differences in the levels of HbA_1c that diminished over time as the HbA_1c levels in the WESDR cohort decreased. The demographic similarities between the DCCT and WESDR cohorts, the similar rates of progression of retinopathy in conventionally treated patients, and the similar associations between the HbA_1c levels and progression of retinopathy in the DCCT and WESDR cohorts support the validity of generalizing the DCCT results to patients with IDDM in the general population.

(Arch Intern Med. 1995;155:745-754)

Author Affiliations
From The Diabetes Control and Complications Trial Research Group, Bethesda, Md.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Relation of Markers of Inflammation and Endothelial Dysfunction to the Prevalence and Progression of Diabetic Retinopathy: Wisconsin Epidemiologic Study of Diabetic Retinopathy
Klein et al.
Arch Ophthalmol 2009;127:1175-1182.
ABSTRACT | FULL TEXT  

Association between Glycosylated Hemoglobin Level and Cardiovascular and All-Cause Mortality in Type 1 Diabetes
Shankar et al.
Am J Epidemiol 2007;166:393-402.
ABSTRACT | FULL TEXT  

Lower-than-Expected Prevalence and Severity of Retinopathy in an Incident Cohort followed during the First 4-14 Years of Type 1 Diabetes: The Wisconsin Diabetes Registry Study
LeCaire et al.
Am J Epidemiol 2006;164:143-150.
ABSTRACT | FULL TEXT  

The Association of Increased Total Glycosylated Hemoglobin Levels with Delayed Age at Menarche in Young Women with Type 1 Diabetes
Danielson et al.
J. Clin. Endocrinol. Metab. 2005;90:6466-6471.
ABSTRACT | FULL TEXT  

Intensive Diabetes Therapy and Carotid Intima-Media Thickness in Type 1 Diabetes Mellitus
The Diabetes Control and Complications Trial/Epide
NEJM 2003;348:2294-2303.
ABSTRACT | FULL TEXT  

Diabetes Care in the U.S. and Canada
Booth et al.
Diabetes Care 2002;25:1149-1153.
ABSTRACT | FULL TEXT  

The Risk of Cardiovascular Disease Mortality Associated With Microalbuminuria and Gross Proteinuria in Persons With Older-Onset Diabetes Mellitus
Valmadrid et al.
Arch Intern Med 2000;160:1093-1100.
ABSTRACT | FULL TEXT  

The Cost-effectiveness of Screening for Type 2 Diabetes
The CDC Diabetes Cost-Effectiveness Study Group
JAMA 1998;280:1757-1763.
ABSTRACT | FULL TEXT  

Lifetime Benefits and Costs of Intensive Therapy as Practiced in the Diabetes Control and Complications Trial
The Diabetes Control and Complications Trial Resea
JAMA 1996;276:1409-1415.
ABSTRACT  

The Benefits of Tight Glycemic Control in Diabetes Mellitus: For the Many or for the Few?
Brancati
Arch Intern Med 1995;155:665-667.
ABSTRACT